menu
    • menu
    [{"orgOrder":0,"company":"Shoreline Biosciences","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Allogeneic Cell Therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Shoreline Biosciences","amount2":2.2999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.2999999999999998,"dosageForm":"","sponsorNew":"Shoreline Biosciences \/ Kite","highestDevelopmentStatusID":"2","companyTruncated":"Shoreline Biosciences \/ Kite"},{"orgOrder":0,"company":"Shoreline Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shoreline Biosciences To Present Two Posters On Ink Cell Platform At 19th Meeting Of The Society For Natural Immunity (NK2022)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"iPSC-NK Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Shoreline Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shoreline Biosciences \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Shoreline Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shoreline Biosciences","sponsor":"Editas Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas iNK Cell Franchise and Related Gene Editing Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"EDIT-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shoreline Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shoreline Biosciences \/ Shoreline Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Shoreline Biosciences \/ Shoreline Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Shoreline Biosciences

    Menu

    Shoreline Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shoreline Biosciences

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Shoreline Biosciences

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EDIT-202

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Editas Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas iNK ...

                            Details : Under the terms of the agreement, Shoreline will acquire EDIT-202, Editas Medicine’s preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors and an additional iNK program under development and certain related manufa...

                            Brand Name : EDIT-202

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 19, 2023

                            Lead Product(s) : EDIT-202

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Editas Medicine

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shoreline Biosciences

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Shoreline Biosciences

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iPSC-NK Cells

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Shoreline Biosciences To Present Two Posters On Ink Cell Platform At 19th Meeting Of The Society For Natural I...

                            Details : Development of an iPSC-derived NK cell screening platform for discovery of NK cell optimized Chimeric Antigen Receptors (CARs) for next-generation CAR-NK cell immunotherapies.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 12, 2022

                            Lead Product(s) : iPSC-NK Cells

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shoreline Biosciences

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Shoreline Biosciences

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Cell Therapies

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Kite Pharma

                            Deal Size : $2,300.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies

                            Details : The collaboration will leverage Shoreline’s deep expertise in iPSC differentiation and genetic reprogramming in combination with Kite’s extensive cell therapy expertise to develop novel allogeneic candidates for a range of hematologic malignancies.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 17, 2021

                            Lead Product(s) : Allogeneic Cell Therapies

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Kite Pharma

                            Deal Size : $2,300.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth